Payment overview · 2025
General Payments
$1,105.47
10 reported records · 5 companies
Healthcare provider profile · identity verified
John D Crawford, MD
Allopathic & Osteopathic Physicians|Family Medicine · GERMANTOWN, TN · NPI 1568406551
Verified facts
What the public records show
CMS Open Payments records show John D Crawford, MD received $1,105.47 in general payments during 2025 across 10 reported records.
Amgen Inc. accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $360.43 | 32.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $343.80 | 31.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $245.86 | 22.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.95 | 10.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $42.43 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,105.47 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $360.43 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $245.86 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $243.32 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.95 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $100.48 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $42.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 104 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
190 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
262 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 808 | 236 |
| Amlodipine Besylate | Amlodipine Besylate | 704 | 204 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 695 | 220 |
| Alprazolam | Alprazolam | 553 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 529 | 137 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 474 | 78 |
| Gabapentin | Gabapentin | 450 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 412 | 128 |
| Furosemide | Furosemide | 383 | 123 |
| Losartan Potassium | Losartan Potassium | 297 | 87 |
| Omeprazole | Omeprazole | 296 | 84 |
| Tramadol Hcl | Tramadol Hcl | 295 | 63 |
| Lisinopril | Lisinopril | 292 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 288 | 86 |
| Mounjaro | Tirzepatide | 262 | 39 |
| Potassium Chloride | Potassium Chloride | 260 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 76 |
| Carvedilol | Carvedilol | 241 | 69 |
| Glyxambi | Empagliflozin/Linagliptin | 228 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 224 | 68 |
| Montelukast Sodium | Montelukast Sodium | 223 | 60 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 208 | 121 |
| Meloxicam | Meloxicam | 197 | 62 |
| Glimepiride | Glimepiride | 196 | 49 |
| Jardiance | Empagliflozin | 190 | 47 |
| Sertraline Hcl | Sertraline Hcl | 188 | 58 |
| Metformin Hcl | Metformin Hcl | 181 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 179 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 52 |
| Allopurinol | Allopurinol | 167 | 48 |
| Eliquis | Apixaban | 155 | 37 |
| Simvastatin | Simvastatin | 152 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 46 |
| Prednisone | Prednisone | 133 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 132 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 43 |
| Donepezil Hcl | Donepezil Hcl | 119 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 35 |
| Azithromycin | Azithromycin | 116 | 80 |
| Ezetimibe | Ezetimibe | 115 | 40 |
| Temazepam | Temazepam | 114 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 114 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 34 |
| Mirtazapine | Mirtazapine | 111 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 110 | 47 |
| Ozempic | Semaglutide | 106 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 106 | 27 |
| Farxiga | Dapagliflozin Propanediol | 104 | 26 |
| Famotidine | Famotidine | 97 | 32 |
| Metformin Hcl Er | Metformin Hcl | 96 | 32 |
| Celecoxib | Celecoxib | 95 | 26 |
| Buspirone Hcl | Buspirone Hcl | 94 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 19 |
| Clonazepam | Clonazepam | 88 | 16 |
| Trazodone Hcl | Trazodone Hcl | 85 | 28 |
| Levofloxacin | Levofloxacin | 83 | 55 |
| Mupirocin | Mupirocin | 83 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 20 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 81 | 19 |
| Nystatin | Nystatin | 81 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 80 | 38 |
| Methocarbamol | Methocarbamol | 76 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 13 |
| Memantine Hcl | Memantine Hcl | 73 | 21 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 71 | 17 |
| Januvia | Sitagliptin Phosphate | 71 | 20 |
| Pregabalin | Pregabalin | 71 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 25 |
| Spironolactone | Spironolactone | 67 | 19 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 66 | 48 |
| Fluconazole | Fluconazole | 64 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 18 |
| Atenolol | Atenolol | 63 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 23 |
| Synthroid | Levothyroxine Sodium | 63 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 14 |
| Cephalexin | Cephalexin | 59 | 31 |
| Irbesartan | Irbesartan | 59 | 16 |
| Telmisartan | Telmisartan | 59 | 15 |
| Gemtesa | Vibegron | 58 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 13 |
| Ramipril | Ramipril | 56 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 13 |
| Meclizine Hcl | Meclizine Hcl | 51 | 20 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 50 | 18 |
| Ondansetron Odt | Ondansetron | 48 | 28 |
| Valacyclovir | Valacyclovir Hcl | 47 | 21 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 46 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 14 |
| Benazepril Hcl | Benazepril Hcl | 45 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Bumetanide | Bumetanide | 42 | 11 |
| Linzess | Linaclotide | 42 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | 11 |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Methotrexate | Methotrexate Sodium | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Finasteride | Finasteride | 34 | 13 |
| Torsemide | Torsemide | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | 11 |
| Hydrocortisone | Hydrocortisone | 33 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Calcitriol | Calcitriol | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 14 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | 14 |
| Zaleplon | Zaleplon | 27 | 18 |
| Baclofen | Baclofen | 26 | suppressed |
| Colchicine | Colchicine | 26 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 16 |
| Lorazepam | Lorazepam | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Testosterone | Testosterone | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Terconazole | Terconazole | 23 | 14 |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 17 |
| Acyclovir | Acyclovir | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 17 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Tobramycin | Tobramycin | 17 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propylthiouracil | Propylthiouracil | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,105.47 · 10 records | Amgen Inc. | BREZTRI, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, Ozempic, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error